All In Biotech

Drug Trial Radar · NCT02973542

Ethosuximide to Treat IBS

Evaluation of the Efficacy and Tolerance of Ethosuximide in the Treatment of Abdominal Pain Associated With Irritable Bowel Syndrome

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

162

Actual

Start

Feb 8, 2018

Primary completion

Mar 7, 2023

Study completion May 7, 2023

Sponsor

Lead sponsor
University Hospital, Clermont-FerrandAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
SFETD (Socièté Française d'Etude et de Traitement de la Douleur)
First posted
Nov 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Abdominal pain remains the most deleterious symptom for patients with irritable bowel syndrome (IBS) and is causing a significant alteration of their quality of life. The visceral hypersensitivity seems to be one of the key mechanisms that could explain the abdominal pain in these patients. Current treatments, mainly symptomatic, are of limited effectiveness, especially in terms of relief of abdominal pain. The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.

Conditions

  • Irritable Bowel Syndrome

Interventions

  • EthosuximideDrug

    The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.

  • PlaceboOther

    The study will aim to evaluate the effectiveness of ethosuximide on abdominal pain in patients with IBS, its tolerance and its impact on patient quality of life, severity of symptoms related to IBS and the use of analgesics / antispasmodic / regulators transit.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 30% reduction in abdominal painTime frame: through study completion, an average of 12 weeks.
  2. Score of 4 or 5 on the SGA scaleTime frame: through study completion, an average of 12 weeks.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.